Evidence map›Paper›PMID 42252503›Full record

ArticleCancer medicine2026

Cancer Prevalence Among Large Cohort of Individuals With Down Syndrome: Implications for Screening Guidelines.

Veronica Fitzpatrick, Akaninyene Noah, Anne Rivelli, Rachel Johnson, Melissa Zak, Joaquin Espinosa, Brian Chicoine

Abstract read
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Veronica FitzpatrickAdvocate Aurora Research Institute, Milwaukee, Wisconsin, USA.ORCID https://orcid.org/0000-0002-0509-3475
Akaninyene NoahAdvocate Aurora Research Institute, Milwaukee, Wisconsin, USA.ORCID https://orcid.org/0000-0003-2002-6147
Anne RivelliAdvocate Aurora Research Institute, Milwaukee, Wisconsin, USA.
Rachel JohnsonAurora Medical Group, Milwaukee, Wisconsin, USA.
Melissa ZakAurora Medical Group, Milwaukee, Wisconsin, USA.
Joaquin EspinosaLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Brian ChicoineAdvocate Health Oak Brook Support Center, Oak Brook, Illinois, USA.ORCID https://orcid.org/0000-0002-1520-3893

Funding

User-ready tools and scalable workflows for INCLUDE datasets in the cloud: advancing brain imaging data management and analyticsU2CHL156291 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI Adam Cain Resnick · 2020 to 2026
$43.8M
NIH HHS U2CHL156291
6 · The paper itself

Abstract

introductionIt is known that individuals with Down syndrome (DS) have a significantly different spectrum of malignancies and neoplasms. Research shows that most solid tumors are less common among individuals with DS compared to the general population, even when adjusted for age. Conversely, individuals with DS are more likely to develop leukemia and testicular cancer. However, very little of this research has been conducted with a US-based population or on large sample sizes.

methodsThis retrospective cohort study analyzed 24 years of EHR data from 5895 unique individuals with DS seen in a Midwestern US health system, with the largest designated DS clinic in the US. We calculated the point prevalence of each cancer type, based on ICD-10 coding, in our DS cohort, examined co-occurrence patterns, and compared prevalence within our sample to the US general population using SEER data from 2022.

resultsIndividuals with DS have significantly lower odds of cancer than the general population (OR = 0.88 (0.77-0.99)). Our cohort was 50.2% less likely to have skin cancer, 80.1% less likely to have cervical cancer, 91% less likely to have prostate cancer, and 90% less likely to have breast cancer. Zero people in our DS cohort had lung cancer. Conversely, our cohort was more likely to have leukemia and testicular cancer.

conclusionThe differences in prevalences indicate a need to consider modification of the cancer screening recommendations for people with DS and inclusion of the information in shared-decision making conversations with the patient and their family.

Indexed as

Down SyndromeEarly Detection of CancerNeoplasmsAdolescentAdultChildChild, PreschoolFemaleHumansMaleMiddle AgedPractice Guidelines as TopicPrevalenceRetrospective StudiesSEER ProgramUnited Statescancerdown syndromehealthcare guidelinesprevalencetrisomy 21

Identifiers

PMID42252503
PMCPMC13243194

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.